Programmi di vaccinazione contro il CoV-19 NON ETICI | ||||
Sponsor(s) | Country | Strategy | Clinical Trial Status | Public Funding |
CanSino Biologics, Inc.
Institute of Biotech., Acad. Military Med. Sciences |
China | Adenovirus vaccine
“Ad5-nCoV”2 HEK293 cells |
NCT04313127
NCT04341389 |
|
University of Oxford
Astrazeneca |
USA
UK |
Adenovirus vaccine
“AZD1222” “ChAdOX1nCoV-19” HEK293 cells |
NCT04324606
NCT04400838 |
HHS-BARDA3
$1.2 billion4 |
Janssen Res. & Devel., Inc.
Johnson & Johnson |
USA | Adenovirus vaccine
“Ad26” PER.C6 cells |
NLF5 | HHS-BARDA
$456,237,0814 |
Univ. of Pittsburgh | USA | Adenovirus expressed
recombinant proteins “PittCoVacc” HEK293 cells |
Pre-clinical | |
Altimmune | USA | Adenovirus vaccine
“AdCOVID” (RD-Ad5) PER.C6 cells |
NLF | |
Programmi di vaccinazione contro il CoV-19 eticamente accettabili | ||||
Shenzhen Geno-immune
Medical Institute |
China | Lentivirus minigenes + Adult human APC6 cells
|
NCT04299724 | |
Shenzhen Geno-immune
Medical Institute |
China | Lentivirus minigenes + Adult human CD/T7 cells
“LV-SMENP-DC” |
NCT04276896 | |
Symvivo Corporation | Canada | Oral bacterium
B. longum, “bacTRL-spike” |
NCT04334980 | |
Moderna, Inc.
with National Institutes of Health |
USA | RNA vaccine
“mRNA-1273” |
NCT04283461
NCT04405076 |
HHS-BARDA
$430,298,5204 |
Inovio Pharmaceuticals | USA | DNA vaccine
“INO-4800” |
NCT04336410 | |
Inovio Pharmaceuticals
Korea Natl. Inst. of Health |
So. Korea | DNA vaccine
“INO-4800” |
CEPI8
$6,900,0009 |
|
Protein Sciences-
Sanofi Co. |
USA | Protein vaccine
Baculovirus expression |
Pre-clinical | HHS-BARDA
$30,775,3364 |
John Paul II
Medical Research Institute |
USA | Recombinant Protein
Perinatal human cells10 |
NLF | |
John Paul II
Medical Research Institute |
USA | Live attenuated virus
Perinatal human cells |
NLF | |
Sanofi & Translate Bio | USA | RNA vaccine | Pre-clinical | |
Sinovac Biotech Co., Ltd. | China | Inactivated CoV-19
“PiCoVacc” Vero monkey cells |
NCT04352608
NCT04383574 |
|
Pfizer and BioNTech | USA
Germany |
RNA vaccine
“BNT-162a1,b1,b2,c2” |
NCT04368728
NCT04380701 |
|
Novavax | USA | Protein vaccine
“NVX-CoV2373” Sf9 insect cells |
NCT04368988 | |
Sorrento | USA | CoV-19 spike protein
Expressed on K562 cells |
||
Arcturus Therapeutics | USA | RNA vaccine | Pre-clinical | |
CureVac | Germany | RNA vaccine | Pre-clinical | CEPI
$34 million11 |
Merck/IAVI | USA | Replication-competent recombinant vesicular stomatitis virus (VSVΔG) Vero monkey cells |
Pre-clinical | HHS-BARDA $38,033,57044 |
Legenda
1 National Institutes of Health, National Library of Science NCT number for clinical trials listed on U.S. clinicaltrials.gov
2 Manufactured by CanSino Biologics, Inc.
3 HHS-BARDA, U.S. Health and Human Services-Biomedical Advanced Research and Development Authority
4 BARDA’s rapidly-expanding COVID-19 medical countermeasure portfolio. 2020. https://www.medicalcountermeasures.gov/app/barda/coronavirus/COVID19.aspx.
5 NLF, no registration listing found (non si è trovato il numero di registrazione)
6 APC, antigen-presenting cells
7 DC/T, dendritic cells and T cells
8 CEPI, Coalition of Epidemic Preparedness Innovations
9 Weil, D. 2020. Inovio gets $6.9M in funding for South Korea coronavirus vaccine trial. The Street. https://www.thestreet.com/investing/inovio-funding-coronavirus-vaccine-trial
10 Donazione volontaria di cordone ombelicale e placenta
11 Christodoulou, M. 2020. CEPI awards US $34million contract to CureVac to advance The RNA Printer™—a mRNA vaccine platform that can rapidly combat multiple diseases. CEPI News. https://cepi.net/news_cepi/cepi-awards-contract-to-curevac-to-advance-the-rna-printer-a-mrna-vaccine-platform-that-can-rapidly-combat-multiple-diseases/
NOTE:
- Coalition of Epidemic Preparedness Innovation. 2020. CEPI publishes analysis of COVID-19 vaccine development landscape. https://cepi.net/news_cepi/cepi-publishes-analysis-of-covid-19-vaccine-development-landscape/.
- Prentice, DA and Sander Lee, T. June 2020. A Visual Aid to Viral Infection and Vaccine Production. On Science Series 1. Accessed June 19, 2020 at: https://lozierinstitute.org/a-visual-aid-to-viral-infection-and-vaccine-production/
- Callaway, E. 2020. The race for coronavirus vaccines: a graphical guide. Nature 580: 576-577. doi: 10.1038/d41586-020-01221-y.
- Kovesdi, I. and Hedley, S. J. 2010. Adenoviral producer cells. Viruses 2(8): 1681-1703. doi: 10.3390/v2081681
- Kochanek, S. and Schiedner, G. 2003. Permanent amniocytic cell line, its production and use for the production of gene transfer vectors. USPTO US6558948B1.
- Watt, H. 27 April 2020. COVID-19 Vaccines and Use of Foetal Cell-lines. The Anscombe Bioethics Centre. Accessed May 4, 2020 at: http://www.bioethics.org.uk/images/user/covidbriefing2.pdf
- Statement from the Department of Health and Human Services, June 5, 2019, accessed February 19, 2020 at: https://www.hhs.gov/about/news/2019/06/05/statement-from-the-department-of-health-and-human-services.html.
- BARDA’s rapidly-expanding COVID-19 medical countermeasure portfolio. 2020. Accessed June 19, 2020 at: https://www.medicalcountermeasures.gov/app/barda/coronavirus/COVID19.aspx.